MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.acvd.2017.04.007

Медицинская библиотека · Archives of cardiovascular diseases · 2017

Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.

De Caterina Raffaele, Brüggenjürgen Bernd, Darius Harald, Köhler Sabine, Lucerna Markus, Pecen Ladislav, Renda Giulia, Schilling Richard John, Schliephacke Tessa, Zamorano José Luis, Le Heuzey Jean-Yves, Kirchhof Paulus

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Non-vitamin K antagonist oral anticoagulants (NOACs) are being introduced for stroke prevention in non-valvular Atrial Fibrillation (AF), and promise to be accepted better than Vitamin K Antagonists (VKAs) by patients, improving their Quality of Life (QoL).

AIM: To assess to what extent patient-related factors influence decisions to switch from a VKA to a NOAC.

METHODS

The PREFER in AF Registry collected data at baseline in 2012 - at the beginning of NOAC prescriptions - and at 1-year follow-up, in 6412 patients in seven Western European countries. QoL and patient satisfaction questionnaires (EQ-5D-5L and/or PACT-Q2) were completed in 3777 patients at both visits. Data were compared across categories of patients on stable treatment with a VKA (i.e. continuously over the previous 12 months) (n=2102) or recently switched (within 12 months) from a VKA to a NOAC (n=213) during a 1-year follow-up, allowing a snapshot of factors influencing the switch at a time when NOACs were being introduced into the market.

RESULTS

Compared to patients on stable treatment with a VKA, switched patients were similar in terms of age, sex, body mass index and other risk factors, but had lower prevalences of hypertension and heart valve dysfunction, and a lower rate of use of concomitant treatment with antiplatelet/anti-inflammatory agents; they also had a lower CHA2DS2-VASc score. Among 25 features investigated, switched patients more often reported bruising or bleeding, complained about bruising, were dissatisfied with the anticoagulant treatment, and reported mobility problems and anxiety/depressive traits.

CONCLUSIONS

At the beginning of NOAC prescriptions, European doctors tended to switch from VKAs to NOACs those patients at lower risk than "non-switchers". Complaints about bruising or bleeding, dissatisfaction with treatment, mobility problems and anxiety/depression traits appear to be related to - and may have influenced - the choice to switch from a VKA to a NOAC.

Для цитирования: De Caterina Raffaele, Brüggenjürgen Bernd, Darius Harald, Köhler Sabine, Lucerna Markus, Pecen Ladislav, Renda Giulia, Schilling Richard John, Schliephacke Tessa, Zamorano José Luis, Le Heuzey Jean-Yves, Kirchhof Paulus. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.. Archives of cardiovascular diseases. 2017. DOI: 10.1016/j.acvd.2017.04.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.